PMID- 20362229
OWN - NLM
STAT- MEDLINE
DCOM- 20100426
LR  - 20191210
IS  - 1873-4456 (Electronic)
IS  - 0165-4608 (Linking)
VI  - 198
IP  - 2
DP  - 2010 Apr 15
TI  - Clinical usefulness of fluorescence in situ hybridization for diagnosis and 
      surveillance of bladder cancer.
PG  - 144-50
LID - 10.1016/j.cancergencyto.2010.01.007 [doi]
AB  - We evaluated the performance of the fluorescence in situ hybridization (FISH) 
      assay in comparison with that of urinary cytology for the detection of bladder 
      urothelial carcinoma in routine clinical practice. Voided urine samples from 602 
      patients with hematuria were analyzed. The bladder cancer group consisted of 95 
      patients who had biopsy-proven bladder cancer, and the control group consisted of 
      507 patients without bladder cancer. We found a significant difference between 
      the overall sensitivities of FISH and cytology (60% vs. 28.4%, respectively; P < 
      0.0001). The overall specificity was 99% with cytology and 94.9% with FISH, 
      although this difference was not statistically significant. The mean values for 
      all four probes in the true-positive group were higher than those in the 
      false-positive group. The difference in the mean values between the two groups 
      was significant only for the CEP3 and CEP17 probes. Furthermore, the severity of 
      the genetic alterations detected by FISH showed a positive correlation with both 
      tumor invasiveness (stage Ta --> T1, T2) and histological grade (G1, G2 --> G3). 
      Together, these findings suggest that FISH can be a useful diagnostic and 
      surveillance tool for patients who are suspected of having new or recurrent 
      bladder cancer.
CI  - Copyright 2010 Elsevier Inc. All rights reserved.
FAU - Song, Min-Jung
AU  - Song MJ
AD  - Department of Laboratory Medicine & Genetics, Samsung Medical Center, 
      Sungkyunkwan University School of Medicine, Gangnam-gu, 135-710 Seoul, Korea.
FAU - Lee, Hyun-Moo
AU  - Lee HM
FAU - Kim, Sun-Hee
AU  - Kim SH
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - United States
TA  - Cancer Genet Cytogenet
JT  - Cancer genetics and cytogenetics
JID - 7909240
SB  - IM
MH  - Aged
MH  - Biopsy
MH  - Carcinoma/*diagnosis/genetics/pathology
MH  - Chromosome Aberrations
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Male
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Sensitivity and Specificity
MH  - Urinary Bladder Neoplasms/*diagnosis/genetics/pathology
EDAT- 2010/04/07 06:00
MHDA- 2010/04/27 06:00
CRDT- 2010/04/06 06:00
PHST- 2009/09/14 00:00 [received]
PHST- 2010/01/08 00:00 [revised]
PHST- 2010/01/12 00:00 [accepted]
PHST- 2010/04/06 06:00 [entrez]
PHST- 2010/04/07 06:00 [pubmed]
PHST- 2010/04/27 06:00 [medline]
AID - S0165-4608(10)00034-8 [pii]
AID - 10.1016/j.cancergencyto.2010.01.007 [doi]
PST - ppublish
SO  - Cancer Genet Cytogenet. 2010 Apr 15;198(2):144-50. doi: 
      10.1016/j.cancergencyto.2010.01.007.